Idarubicin Brand Name– Idamycin PFS
What is Idarubicin
Idarubicin is an anthracycline chemotherapy agent indicated in combination with other approved antileukemic agents for the treatment of adults with acute myeloid leukemia including French-American-British classifications M1 through M7.
Cardiotoxicity and severe myelosuppression have been reported with idarubicin therapy; monitoring is recommended.
Indications
- acute lymphocytic leukemia (ALL)
- acute myelogenous leukemia (AML)
- acute promyelocytic leukemia
- chronic myelogenous leukemia (CML)
- non-Hodgkin’s lymphoma (NHL)
For the treatment of acute myelogenous leukemia (AML)
NOTE: Idarubicin has been designated an orphan drug by the FDA for the treatment of AML.
for remission induction therapy in AML, in combination with other approved antileukemic drugs including cytarabine
Side Effects
- abdominal pain
- alopecia
- anemia
- atrial fibrillation
- AV block
- bleeding
- bone marrow suppression
- bradycardia
- bullous rash
- cardiomyopathy
- cardiotoxicity
- chest pain (unspecified)
- diarrhea
- elevated hepatic enzymes
- enterocolitis
- fever
- GI perforation
- headache
- heart failure
- infection
- injection site reaction
- leukopenia
- myocardial infarction
- nausea
- nausea
- neutropenia
- oral ulceration
- oral ulceration
- pancytopenia
- peripheral neuropathy
- premature ventricular contractions (PVCs)
- QT prolongation
- radiation recall reaction
- rash
- seizures
- sinus tachycardia
- ST-T wave changes
- supraventricular tachycardia (SVT)
- thrombocytopenia
- tissue necrosis
- urticaria
- ventricular tachycardia
- vomiting
- vomiting
Monitoring Parameters
- CBC
- echocardiogram
- LFTs
- serum creatinine/BUN
Contraindications
- accidental exposure
- acute myocardial infarction
- angina
- anthracycline hypersensitivity
- bone marrow suppression
- breast-feeding
- cardiac arrhythmias
- cardiac disease
- cardiotoxicity
- children
- dental disease
- dental work
- extravasation
- heart failure
- hepatic disease
- herpes infection
- hyperkalemia
- hyperphosphatemia
- hyperuricemia
- hypocalcemia
- infection
- intramuscular administration
- intramuscular injections
- jaundice
- maximum cumulative lifetime dose
- neutropenia
- ocular exposure
- pregnancy
- radiation therapy
- renal impairment
- requires a specialized care setting
- requires an experienced clinician
- subcutaneous administration
- thrombocytopenia
- tumor lysis syndrome (TLS)
- vaccination
- varicella
- ventricular dysfunction
- viral infection
Interactions
- Cyclophosphamide
- Gadobenate Dimeglumine
- Palifermin
- Penicillamine
- Trastuzumab
- Trastuzumab; Hyaluronidase
- Tuberculin Purified Protein Derivative, PPD
